SCHOLAR ROCK HOLDING CORP (SRRK) Stock Overview
USA - NASDAQ:SRRK - US80706P1030 - Common Stock
SRRK Key Statistics, Chart & Performance
The current stock price of SRRK is 40.99 USD. In the past month the price increased by 28.74%. In the past year, price increased by 54.62%.
SRRK Latest News, Press Relases and Analysis
SRRK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.78 | 407.53B | ||
| AMGN | AMGEN INC | 13.55 | 159.05B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 144.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.49 | 106.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.49 | 60.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.90B | ||
| ARGX | ARGENX SE - ADR | 86.83 | 49.26B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.42 | 36.88B | ||
| INSM | INSMED INC | N/A | 34.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.12B | ||
| NTRA | NATERA INC | N/A | 23.75B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About SRRK
Company Profile
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Company Info
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 128
Phone: 18572593860
SCHOLAR ROCK HOLDING CORP / SRRK FAQ
What is the stock price of SCHOLAR ROCK HOLDING CORP today?
The current stock price of SRRK is 40.99 USD. The price increased by 5.94% in the last trading session.
What is the ticker symbol for SCHOLAR ROCK HOLDING CORP stock?
The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.
On which exchange is SRRK stock listed?
SRRK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCHOLAR ROCK HOLDING CORP stock?
18 analysts have analysed SRRK and the average price target is 48.96 USD. This implies a price increase of 19.44% is expected in the next year compared to the current price of 40.99. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCHOLAR ROCK HOLDING CORP worth?
SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.94B USD. This makes SRRK a Mid Cap stock.
How many employees does SCHOLAR ROCK HOLDING CORP have?
SCHOLAR ROCK HOLDING CORP (SRRK) currently has 128 employees.
What are the support and resistance levels for SCHOLAR ROCK HOLDING CORP (SRRK) stock?
SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 40.97. Check the full technical report for a detailed analysis of SRRK support and resistance levels.
Should I buy SCHOLAR ROCK HOLDING CORP (SRRK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRRK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRRK, evaluating the profitability, health, valuation and growth aspects
- SCHOLAR ROCK HOLDING CORP (SRRK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCHOLAR ROCK HOLDING CORP (SRRK) Sales and EPS estimates to see what analysts future expectations are.
- SCHOLAR ROCK HOLDING CORP (SRRK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCHOLAR ROCK HOLDING CORP (SRRK) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCHOLAR ROCK HOLDING CORP (SRRK) Stock Chart to make your own analysis
- SCHOLAR ROCK HOLDING CORP (SRRK) Latest news and press-releases to stay up to date.
Does SCHOLAR ROCK HOLDING CORP (SRRK) stock pay dividends?
SRRK does not pay a dividend.
When does SCHOLAR ROCK HOLDING CORP (SRRK) report earnings?
SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of SCHOLAR ROCK HOLDING CORP (SRRK)?
SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
What is the Short Interest ratio of SCHOLAR ROCK HOLDING CORP (SRRK) stock?
The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 17.54% of its float. Check the ownership tab for more information on the SRRK short interest.
SRRK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 86.11% of all stocks.
SRRK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability.
SRRK Financial Highlights
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS decreased by -31.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.84% | ||
| ROE | -135.32% | ||
| Debt/Equity | 0.21 |
SRRK Forecast & Estimates
18 analysts have analysed SRRK and the average price target is 48.96 USD. This implies a price increase of 19.44% is expected in the next year compared to the current price of 40.99.